TREA

87837595 - AW ACTAVIS

Follow

Information

  • Trademark
  • 87837595
  • Serial Number
    87837595
  • Filing Date
    March 16, 2018
    6 years ago
  • Transaction Date
    June 21, 2022
    2 years ago
  • Status Date
    June 20, 2022
    2 years ago
  • Published for Opposition Date
    March 19, 2019
    5 years ago
  • Location Date
    November 16, 2021
    2 years ago
  • Status Code
    606
  • Current Location
    INTENT TO USE SECTION
    Employee Name
    BLACK, MILDRED ELIZABE
  • Attorney Name
    Laurence Rickles
    Law Office Assigned Location Code
    N30
  • Owners
Information
Mark Drawing Code
3000
Mark Identification
AW ACTAVIS
Case File Statements
  • DM0000: The mark consists of the word "ACTAVIS" below the letters "A" and "W", which appear in an intertwined fanciful lettering style that resembles a horizontal zig-zag line or a coil, which are both displayed in the color white. The word "ACTAVIS" and the letters "A" and "W" are centered within a rectangle displayed in the color gray.
  • GS0051: Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines affecting sensory organs; Pharmaceuticals and medicines affecting the central nervous system; Pharmaceuticals and medicines affecting urogenital organs; Pharmaceuticals and medicines affecting circulatory systems; Pharmaceuticals and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceuticals and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, neurological disorders, neurodegenerative disorders, and depression, antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceuticals used in connection with anti-aging, the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, facial aesthetic surgery, facial aesthetic reconstruction, breast aesthetics; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma and decongestant formulations; sterile antibiotic, anti-inflammatory ointments; ocular wetting solutions, artificial tears and formulations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lighteners; Pharmaceuticals and cosmeceuticals, namely, medicated skin cleansers, toners, moisturizers, rejuvenators, rehydrating creams, and lotions for the face and body
  • CC0000: The color(s) gray and white is/are claimed as a feature of the mark.
Case File Event Statements
  • 6/21/2022 - 2 years ago
    39 - ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED Type: MAB6
  • 6/20/2022 - 2 years ago
    38 - ABANDONMENT - NO USE STATEMENT FILED Type: ABN6
  • 11/17/2021 - 2 years ago
    37 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Type: EXRA
  • 11/16/2021 - 2 years ago
    36 - SOU EXTENSION 5 GRANTED Type: EX5G
  • 11/9/2021 - 2 years ago
    35 - SOU EXTENSION 5 FILED Type: EXT5
  • 11/16/2021 - 2 years ago
    34 - CASE ASSIGNED TO INTENT TO USE PARALEGAL Type: AITU
  • 11/9/2021 - 2 years ago
    33 - TEAS EXTENSION RECEIVED Type: EEXT
  • 5/18/2021 - 3 years ago
    32 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Type: EXRA
  • 5/14/2021 - 3 years ago
    31 - SOU EXTENSION 4 GRANTED Type: EX4G
  • 5/14/2021 - 3 years ago
    30 - SOU EXTENSION 4 FILED Type: EXT4
  • 5/14/2021 - 3 years ago
    29 - TEAS EXTENSION RECEIVED Type: EEXT
  • 11/7/2020 - 3 years ago
    28 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Type: EXRA
  • 11/5/2020 - 3 years ago
    27 - SOU EXTENSION 3 GRANTED Type: EX3G
  • 11/5/2020 - 3 years ago
    26 - SOU EXTENSION 3 FILED Type: EXT3
  • 11/5/2020 - 3 years ago
    25 - TEAS EXTENSION RECEIVED Type: EEXT
  • 5/14/2020 - 4 years ago
    24 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Type: EXRA
  • 5/12/2020 - 4 years ago
    23 - SOU EXTENSION 2 GRANTED Type: EX2G
  • 5/12/2020 - 4 years ago
    22 - SOU EXTENSION 2 FILED Type: EXT2
  • 5/12/2020 - 4 years ago
    21 - TEAS EXTENSION RECEIVED Type: EEXT
  • 7/13/2019 - 4 years ago
    20 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Type: EXRA
  • 7/11/2019 - 4 years ago
    19 - SOU EXTENSION 1 GRANTED Type: EX1G
  • 7/11/2019 - 4 years ago
    18 - SOU EXTENSION 1 FILED Type: EXT1
  • 7/11/2019 - 4 years ago
    17 - TEAS EXTENSION RECEIVED Type: EEXT
  • 5/14/2019 - 5 years ago
    16 - NOA E-MAILED - SOU REQUIRED FROM APPLICANT Type: NOAM
  • 3/19/2019 - 5 years ago
    15 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 3/19/2019 - 5 years ago
    14 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 2/27/2019 - 5 years ago
    13 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 2/11/2019 - 5 years ago
    12 - ASSIGNED TO LIE Type: ALIE
  • 1/26/2019 - 5 years ago
    11 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 1/9/2019 - 5 years ago
    10 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 1/9/2019 - 5 years ago
    9 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 1/9/2019 - 5 years ago
    8 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 7/9/2018 - 6 years ago
    7 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN
  • 7/9/2018 - 6 years ago
    6 - NON-FINAL ACTION E-MAILED Type: GNRT
  • 7/9/2018 - 6 years ago
    5 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 6/27/2018 - 6 years ago
    4 - ASSIGNED TO EXAMINER Type: DOCK
  • 3/24/2018 - 6 years ago
    3 - NOTICE OF DESIGN SEARCH CODE E-MAILED Type: MDSC
  • 3/23/2018 - 6 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM Type: NWOS
  • 3/20/2018 - 6 years ago
    1 - NEW APPLICATION ENTERED IN TRAM Type: NWAP